Short-lasting unilateral neuralgiform headache attacks are primary headache disorders characterized by short-lasting attacks of unilateral pain accompanied by autonomic features. A small minority are refractory to medical treatment. Neuroimaging studies have suggested a role of the posterior hypothalamic region in their pathogenesis. Previous case reports on deep brain stimulation of this region, now understood to be the ventral tegmental area, for this disorder are limited to a total of three patients. We present a case series of 11 new patients treated with ventral tegmental area deep brain stimulation in an uncontrolled, open-label prospective observational study. Eleven patients with refractory short-lasting unilateral neuralgiform headache attacks underwent ipsilateral ventral tegmental area deep brain stimulation in a specialist unit. All patients had failed, or been denied access to, occipital nerve stimulation within the UK's National Health Service. Primary endpoint was change in mean daily attack frequency at final followup. Secondary outcomes included attack severity, attack duration, headache load (a composite score of attack frequency, severity and duration), quality of life measures, disability and affective scores. Information was also collected on adverse events. Eleven patients (six male) with a median age of 50 years (range 26-67) were implanted between 2009 and 2014. Median follow-up was 29 months (range 7-63). At final follow-up the median improvement in daily attack frequency was 78% (interquartile range 33%). Response rate (defined as at least a 50% improvement in daily attack frequency) was 82% and four patients were rendered painfree for prolonged periods of time. Headache load improved by 99% (interquartile range 52%). Improvements were observed in a number of quality of life, disability and affect measures. Adverse events included mild incision site pain, subcutaneous displacement of the implantable pulse generator, transient oscillopsia and minor wound infection. One patient required removal of the system due to wound infection. Ventral tegmental area deep brain stimulation may be an effective treatment option for refractory shortlasting unilateral neuralgiform headache attack patients who have failed other therapies. 
Introduction
Short-lasting unilateral neuralgiform headache attacks are a rare form of primary headache disorders characterized by frequent attacks of excruciating unilateral pain occurring in the trigeminal distribution, centred on the eye and temple, with associated autonomic features. They are included in the group known as the trigeminal autonomic cephalalgias and The International Classification of Headache Disorders (ICHD3-beta) describes two subtypes (Table 1) : shortlasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic features (SUNA) (Headache Classification Committee of the International Headache Society, 2013). The disorder is said to be chronic when it occurs for more than a year with remission periods lasting less than 1 month. Short-lasting unilateral neuralgiform headache attacks can be difficult to treat medically. In the past, intractable patients have been subjected to destructive procedures of the trigeminal nerve with poor long-term results (Black and Dodick, 2002) . Peripheral [occipital nerve stimulation (ONS)] and central [ventral tegmental area (VTA) deep brain stimulation (DBS)] neuromodulation techniques have been carried out with more promising results (Leone et al., 2005; Lyons et al., 2009; Bartsch et al., 2011; Lambru et al., 2014) .
To date there are three published case reports of DBS for short-lasting unilateral neuralgiform headache attacks (Leone et al., 2005; Lyons et al., 2009; Bartsch et al., 2011) . We present a consecutive series of 11 patients with intractable chronic short-lasting unilateral neuralgiform headache attacks treated with VTA-DBS as a humanitarian intervention reporting on changes in attack characteristics, quality of life, headache disability, affect scores and adverse events.
Patients and methods
This was an observational study based on a prospective, open label cohort initiated in 2009. Under the supervision of our institution's Clinical Effectiveness Supervisory Committee with arrangements for clinical governance, consent and audit, we offered VTA-DBS to medically intractable short-lasting unilateral neuralgiform headache attacks who had failed ONS or had been declined NHS funding for ONS. The procedure was provided on the basis of a 'humanitarian intervention'. In addition, ethic board approval for data collection and publication was granted by Northwick Park Hospital Research Ethics Committee, Hampstead, London, UK.
All patients were seen by a single specialist headache team at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK and referred to a single multidisciplinary DBS team at the same centre. All patients fulfilled the ICDH-2 criteria at diagnosis but also met revised ICHD-3beta criteria (Headache Classification Subcommittee of the International Headache Society, 2004; Headache Classification Committee of the International Headache Society, 2013). Patients with prolonged attacks had a trial of indometacin (oral or intramuscular) to rule out indometacinsensitive headaches (Antonaci et al., 2003) . Unlike chronic cluster headache or chronic migraine, intractability is not defined for short-lasting unilateral neuralgiform headache attacks . Patients were considered suitable for VTA-DBS if they had had disabling medically intractable chronic short-lasting unilateral neuralgiform headache attacks for at least 2 years and had failed adequate trials of lamotrigine, topiramate, gabapentin, pregabalin and at least one of either carbamazepine or oxcarbazepine (Lambru et al., 2014) . Disability was defined as a Headache Impact Test Score (HIT-6) in the severely affected range (460). Agents were selected based on reported efficacy in this disorder and local experience (Cohen et al., 2006; Williams and Broadley, 2008) . A failed trial was defined as lack of response, intolerable side effects or contradiction to the use of the drug. One patient (Patient P9) did not meet the criteria for medical intractability as they had not trialled carbamazepine or oxcarbazepine but this patient was implanted primarily for co-existent intractable chronic cluster headache. All patients were considered for ONS prior to VTA-DBS and had either been declined funding or failed to respond. Microvascular decompression of the trigeminal nerve was not being offered to this patient group during the study period. Neuropsychological evaluations and MRI brain scans were performed to exclude possible contraindications to surgery such as significant cognitive impairment, brain lesion or significant brain atrophy.
Outcomes
The two primary outcome measures were the change in median daily attack frequency in the 2 weeks prior to implant and the 2 weeks before final follow-up with clinical response to VTA-DBS, defined as a minimum 50% reduction in daily attack frequency. Secondary outcomes included reduction in the daily attack severity and frequency, headache-specific disability scores, quality of life and affect scores.
Outcome data were collected and recorded prospectively. Patients were seen at 3-monthly intervals post-implant over the first year and 6-monthly thereafter. Timing of additional appointments was dependent on clinical condition. Data collected included demographics, diagnosis, previous and current treatments, attack frequency, attack severity, headache load (HAL), headache disability scores, quality of life scales, affective scores, DBS settings and complications.
HAL is a composite score defined as AE[severity (verbal rating scale)] Â [duration (h)] of all attacks over a 2-week period (Levy et al., 2004) . Patients were asked to record these data in a headache diary completed for at least 2 weeks before every assessment. Headache severity was measured on a verbal rating scale (VRS; 0 = no pain, 10 = excruciating pain). Patients with multiple headache types were able to differentiate their phenotypes and kept a separate diary for each headache syndrome.
Although specific tools for measuring the associated disability of trigeminal autonomic cephalalgias have yet to be validated, Migraine Disability Assessment Scores (MIDAS) and HIT-6 were recorded pre-and post-DBS to monitor disability. These scores have been widely used in the assessment of primary headache disorders and have previously been used to monitor response to cluster headache, hemicrania continua and short-lasting unilateral neuralgiform disorders in ONS (Schwedt et al., 2007; Burns et al., 2009; Lambru et al., 2014) . Beck Depression Inventory II Score (BDI-II), Hospital Anxiety (HAD-A) and Depression (HAD-D) scores were used to monitor mental state pre-and post-ONS implant and quality of life was assessed using the EuroQoL (EQ-5D) and ShortForm 36 (SF-36).
Data were collected prospectively and entered onto a clinical database (Microsoft Excel, Microsoft Corporation, Redmond, WA, USA).
Surgical procedure
DBS surgery was performed with the Leksell frame (model G, Elekta Instrument AB), using an MRI-guided and MRI-verified approach without microelectrode recording. This approach has previously been described for alternative DBS targets (Holl et al., 2010; Foltynie et al., 2011) . Surgery was performed under local anaesthesia for Patients 1-4 and under general anaesthesia for all others (Patients P5-11). The anatomical target was the VTA ipsilateral to the side of attacks. The location of the deepest contact of the Medtronic 3389 lead was defined on an axial 1.5 T T 2 -weighted stereotactic MRI image at a level immediately superior to the mammillary bodies, anteromedial to the hypointense red nucleus and posterolateral to the hypointense mammillothalamic tract. Lead position was verified during surgery using a stereotactic MRI (or stereotactic CT in Patient 9 with ONS in situ) (Fig. 1 ). All DBS leads were located within 1 mm of the intended target point. All DBS leads were implanted within 1 mm of the intended target point. The lead was then connected to a Medtronic implantable pulse generator (IPG) located in the infra-clavicular region.
Deep brain stimulation programming
All patients underwent initial programming to define optimal stimulation parameters. The contact point that produced typical patient complaints of transient vertical diplopia, vertigo, oscillopsia and ophthalmoplegia at the lowest amplitudes was chosen as the initial stimulation contact. Four patients had stimulation started immediately. The remaining seven patients had a delay of 4-7 weeks before stimulation was started as they exhibited a stun effect postoperatively where attacks transiently improved without use of stimulation. In those with a stun effect, DBS was not initiated until attacks returned to normal presurgical frequency. All devices were programmed with frequency of 185 Hz and a 60 ms pulse width. Voltage was adjusted according to patient reported side effects (see above) aiming for a maximum of 4.0 V. Adjustments in voltage were undertaken in single or multiple steps dependent on patient tolerability. Stimulation parameters remained constant for 3 months after each reprogramming session. Adjustments in stimulation parameters were made depending on clinical response.
Statistics
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. Int.). In descriptive analysis, continuous variables were summarized using median and interquartile range and categorical variable using percentages. Wilcoxon signed-rank tests were used to measure changes in baseline values. A last observation carried forward technique was used in the case of missing data. All statistical tests were two-sided with a significance level of 5%. 
Results

Patient demographics
Eleven patients (six male) with short-lasting unilateral neuralgiform headache attacks underwent VTA-DBS between October 2009 and September 2014. Patient demographics and baseline headache characteristics are shown in Table 2 . Median age at implant was 50 years (range 26-67). Three patients were diagnosed with SUNA and eight with SUNCT. Nine patients had been chronic since onset. Median duration of the chronic phase was 9 years (range 4-20). Five patients had additional headache syndromes including chronic migraine (three patients), chronic cluster headache (CCH, three patients) ( Table 2 ). In those with cluster headache, attacks of short-lasting unilateral neuralgiform headache attacks were ipsilateral to their cluster attacks in all but one patient (Patient P9), who had left-sided cluster attacks and unilateral but side variable SUNCT attacks (more common on the left). Eight patients had unilateral DBS electrodes implanted and three had bilateral implants (Patients P7, P9 and P10) for side variable attacks (Supplementary Table 4 ). Two patients (Patients P5 and P9) had previously undergone ONS implantation with little (Patient P9) or no effect (Patient P5) on their SUNCT. Patient 5 had had the ONS device removed prior to VTA-DBS and Patient 10 still had the ONS in situ given its partial effect on their cluster headaches. All patients had undergone MRI brain scans prior to VTA-DBS of which two showed evidence of neurovascular conflict of the ipsilateral trigeminal nerve.
Patients had tried a median of 11 treatments [interquartile range (IQR) 3] including oral preventative drugs and injectable treatments (Supplementary Tables 1 and 2) . Nine of ten patients that received lidocaine infusions reported transient benefit and 10 patients failed to receive any benefit from greater occipital nerve blocks.
Follow-up and final outcome
Postoperative follow-up ranged from 7-63 months with a median of 29 months (IQR 20) . One patient had her DBS system removed at time of follow-up.
At final follow-up, median attack frequency had reduced by 78% (IQR 33) from 45 (IQR 10) to 2 (IQR 180) attacks per day (P = 0.003) ( Fig. 2A and B and Table 3 ). A positive clinical response, defined as at least a 50% reduction in attack frequency, was seen in 82% (nine patients).
Of the two who failed to respond, one (Patient P5) had the stimulator switched off for $12 months during the 32-month follow-up due to tolerability issues but still obtained a more than 30% reduction in attacks. The other (Patient P6), reporting a 25% reduction in attack frequency at follow-up, did not have an implant in situ having had the DBS system removed 17 months into her 24 month followup due to a wound infection. Previous to implant removal, the patient was reporting a 90% reduction in daily attack frequency (Fig. 2B) .
Patient estimate of improvement was 70% (IQR 95%) (Table 3 ) and all patients said they would recommend the treatment to others. The median time to reach a 50% improvement was 1 month (range 1-2 months). Only one responder had the system switched off for any period of time (Patient P6) and attack frequency returned to baseline within 1 month of DBS removal.
In those with co-existent headache disorders, cluster headache attacks decreased in two patients (Patients P3 and P9) by 72% and 25%, respectively. Migrainous headaches failed to respond in the three patients (Patients P3, P6 and P10) reporting them.
Attack severity, duration and headache load
At final follow-up, median attack severity reduced by 50% from 10 (IQR 2) to 5 (IQR 10) points on Verbal Rating Scale (P = 0.020). Median attack duration reduced by 99% (IQR 100) from 7200 to 30 s but this change was not statistically significant (P = 0.066). HAL showed a median reduction of 99% (IQR 52) (P = 0.026). Neither of the patients categorized as clinical non-responders (Patients P5 and P6) showed a 450% reduction in HAL. One patient (Patient P9) who recorded a 66% reduction in attack frequency failed to show a matching response to HAL (48% reduction) ( Table 3 ). Headache-associated disability scores, quality of life and affect measures Baseline median MIDAS and HIT-6 scores were 81 (IQR 254) and 70 (IQR 12), respectively, both scores being within the severely affected range (Table 4) . At final follow-up statistically significant reductions were seen in HIT-6 but not MIDAS. Median HIT-6 fell by 15 points (P = 0.015) well above the 3-point minimally important change (Smelt et al., 2014) . MIDAS fell by 39 points (P = 0.678), which although not statistically significant is above the 9-point difference separating moderate from severe disability.
Summary measures of the physical (SF-36P) and mental (SF-36M) SF-36 scale showed a non-significant improvement (Table 3) . No significant change was seen in the separate domain scores of SF-36 scale (Fig. 3) . Euro-QoL 5D and EuroScale scores did not show any significant change post-implant (Table 4) . Prior to implant all affective scores indicated the presence of moderate mood disorders. Posttreatment, both HAD-A and BDI-II scales indicated mild disorder scores but HAD-D continued to indicate moderate levels of depression (Table 4) . Despite this clinical change, there was no statistically significant change in affective scores at follow-up.
Adverse events
Adverse events were recorded if any issues had arisen during the time of treatment. Events were classified as 'hardware related' if they involved a malfunction of any device component, 'biological' if they involved pain or other biological reactions related to the device or the surgical procedure to implant it and 'stimulation-related' if they were thought to be related to stimulation. One hardware-related event was noted with a patient requiring surgical revision of their implantable pulse generator due to it moving or 'flipping'. Biological adverse events included mild-to-moderate neck stiffness in three patients, keloid scar in one patient and persistent pain over wound sites in two patients. One patient suffered a small wound dehiscence in the first 3 weeks postoperatively with no evidence of wound infection. One patient suffered a wound infection at the lead/cable connector site 17 months post-implant (Patient P6). Due to the risk of spread of infection, the whole DBS system was removed. All patients reported transient stimulation-related adverse effects (described above) related to DBS programming resolving within minutes to hours. One patient complained of symptoms compatible with oscillopsia on reading for 6 weeks after their initial programming session that resolved spontaneously. One patient (Patient P5) complained of intolerable worsening of chronic nausea with any change in stimulation, however, with blinded changes in stimulation and in a 12-month period without stimulation there was no change in the Table 2 nausea and it was judged that this complaint was not related to stimulation. A total of two surgical interventions were required during follow-up (Table 5 ).
Concomitant drug use
Nine patients were taking preventative medications for short-lasting unilateral neuralgiform headache attacks at time of implant (Supplementary Table 3 ). At final followup, four patients had stopped all preventatives for their SUNCT/SUNA and a further two had been able to reduce their doses of one or more medications.
Stimulation parameters
A summary of stimulation parameters is given in Supplementary Table 4 . Median stimulation amplitude at follow-up was 3.0 V. Subjects had a median of six changes to stimulation parameters during follow-up.
Discussion
Previous case reports of VTA-DBS treatment in shortlasting unilateral neuralgiform headache attacks have suggested a benefit in three patients (Leone et al., 2005; Lyons et al., 2009; Bartsch et al., 2011) . Our open-label prospective series of 11 patients suggests that VTA-DBS may be an effective and safe treatment in patients with intractable short-lasting unilateral neuralgiform headache attacks who have proved refractory to all other available treatment modalities. In our group of 11 patients there was a significant reduction in daily attack frequency of 78% with four patients remaining pain-free for prolonged periods of time.
Overall nine patients had a positive response to VTA-DBS with a 50% or more reduction in attack frequency. Improvement was seen in headache-specific disability scores (HIT-6) but not in quality of life scales or measures of depression. Deep brain stimulation for another trigeminal autonomic cephalalgia CCH was first undertaken by Leone et al. (2001). This procedure was based on the findings of a 1998 study, which showed increased activation on PET in the posterior hypothalamic region during cluster headache attacks (May et al., 1998) . To date, there are now published data on over 70 patients with intractable CCH treated with DBS. One series, which pools 58 of these patients, reports that 62% showed a 50% or greater reduction in attack frequency (Magis and Schoenen, 2012) . Similar findings of activation of the ipsilateral inferior posterior hypothalamic region was also observed during SUNCT attacks and therefore the same DBS target was proposed to be potentially beneficial in the treatment of short-lasting unilateral neuralgiform headache attacks (May et al., 1999) . Only three case reports have been published, all showing substantial and sustained reductions in attack frequency without any serious adverse events (Leone et al., 2005; Lyons et al., 2009; Bartsch et al., 2011) . Since the initial work of May and Leone, further anatomical clarification of the surgical target has been undertaken and the target has been shown to be in the VTA of the midbrain rather than the posterior hypothalamic region (Fontaine et al., 2010a; Matharu and Zrinzo, 2010) .
Our series shows improvements in both attack frequency (78%) and severity (50%) with VTA-DBS. This finding has been described in CCH cases treated with VTA-DBS but not short-lasting unilateral neuralgiform headache attack cases (Magis and Schoenen, 2012) . This series also reports the HAL as an outcome measure for the group. This composite score reflects all three domains of headache burden (frequency, severity and duration). Attack frequency has always been the focus of previous outcome reports for VTA-DBS for headache. However, the use of a single outcome may not represent the actual benefit perceived by the patient. HAL showed a significant improvement (99%) at final follow-up. In our group, only one patient showed a discrepancy between attack frequency and HAL response (Patient P9). This patient exhibited a 66% reduction in attack frequency (and so a positive response to VTA-DBS) but a 48% reduction in HAL. It is interesting to note that this patient stated they had not perceived any benefit from the treatment. The clinical usefulness of HAL as a primary outcome measure needs validation in larger cohorts in the future.
As in previous VTA-DBS for primary headache series, our subjects reported a delay in clinical response. In CCH this delay is several months long but in the short-lasting unilateral neuralgiform headache cases ranged from days to a maximum of 3 months (Leone et al., 2005; Burns et al., 2009; Lyons et al., 2009; Bartsch et al., 2011; Magis et al., 2011; Magis and Schoenen, 2012) . In our series, the time taken to see positive clinical response was 1 month (range 1-2 months). This delay likely reflects the neuroplastic response underlying successful VTA-DBS treatment.
Clinically and statistically important differences were seen in HIT-6 scores following VTA-DBS but no significant improvement was seen in quality of life measures. Factors to consider in this observation include the small sample Table 3 size, the long duration of chronic pain (9 years) and comorbidities in these patients, all of which may have resulted in psychosocial issues unlikely to improve with change in symptoms. Similar observations have been made in VTA-DBS for CCH (Bartsch et al., 2008) . Little has been published regarding quality of life data in the trigeminal autonomic cephalalgias including short-lasting unilateral neuralgiform attack disorders and no specific headache disability or quality of life scales exist for these disorders. It has been suggested that in headache disorders, generic scales (such as SF-36) may not be useful in measuring changes over time and that disorder-specific measures (such as HIT-6) may be more representative (Solomon, 1997) . Until such scales have been developed, the quality of life tools available may not accurately reflect the headache groups they are applied to. Only one serious adverse event occurred with subcutaneous infection that led to system removal in this series. Infection of the DBS system has been reported by two other CCH series (4/19 and 1/11 patients) (Fontaine et al., 2010b; Leone et al., 2013) , although their operative technique differed from our unit. The death of a patient from an intracerebral haemorrhage following microelectrode (MER) guided DBS for CCH has raised serious safety concerns regards this procedure (Schoenen et al., 2005) . However, there is no recognized neuronal firing pattern or 'signature' for the VTA, casting doubt on the clinical utility of MER for this anatomical target. Moreover, the use of an MRI-verified surgical technique without the use of MER provides direct visualization of the individual target area and is associated with a significantly lower risk of haemorrhage during DBS procedures (Zrinzo et al., 2012) . The use of microelectrode recording when targeting this area has also been avoided by using an endoventricular approach to DBS lead placement (Chabardes et al., 2016) . The stimulation induced ophthalmic side effects reported by our patients have all been documented in CCH series and, much like our series, have all been transient. It is likely that this transient vertical diplopia is due to stimulation of the nearby rostral interstitial nucleus of the medial longitudinal fasciculus that forms part of the vertical gaze centre (Buttner-Ennever et al., 1982) .
The main limitation of this study is the lack of placebo control. Although there is undoubtedly a placebo effect for headache treatments, it is unlikely our findings can be explained by this alone. Placebo response rates for ONS in migraine are low (520%) and there is no reason to expect the contrary in this disorder or procedure (Lipton et al., 2009; Saper et al., 2011; Silberstein et al., 2012) . Likewise, the intractable nature of the group, the sustained response and the re-emergence of attacks when stimulation was stopped all argue against a placebo response. Although a previous randomized controlled trial of DBS in CCH failed to show a difference between sham and active stimulation, this was likely due to methodological issues with short 1-month crossover periods. Unfortunately, given the rarity of short-lasting unilateral neuralgiform headache attacks it seems unlikely that high quality, properly powered randomized control trials of VTA-DBS will ever be performed. Microvascular decompression, occipital nerve stimulation and DBS have all been found to be effective in open-label series with response rates of over 75% (Leone et al., 2005; Bartsch et al., 2011; Sebastian et al., 2013; Lambru et al., 2014) . The invasiveness of surgery, associated risks, the need for implanted hardware and the cost of treatment will all influence individual patient options. With these in mind, we may in the future recommend that patients with intractable short-lasting unilateral neuralgiform headache attacks first undergo microvascular decompression if they have ipsilateral neurovascular compression of the trigeminal nerve, that ONS be reserved for those without neurovascular compression or failing microvascular decompression and DBS (as the most invasive neuromodulation option) be left as an option when patients have failed all other procedures.
This study suggests that VTA-DBS may provide an effective and sustained benefit in intractable short-lasting unilateral neuralgiform headache attacks. However, MRI-verified VTA-DBS should be reserved for those patients having failed all other medical and surgical options available to them. 
